158 related articles for article (PubMed ID: 37698159)
1. Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy.
Chen L; Ding S; Cheng Y; Zhou L; Yan J; Cheng Q; Jin A; Zhou X; Huang H; Hu Y
Eur J Haematol; 2024 Feb; 112(2):257-265. PubMed ID: 37698159
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
3. Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies.
Wang Y; Qi K; Cheng H; Cao J; Shi M; Qiao J; Yan Z; Jing G; Pan B; Sang W; Li D; Wang X; Fu C; Zhu F; Zheng J; Li Z; Xu K
Biol Blood Marrow Transplant; 2020 May; 26(5):865-875. PubMed ID: 31786240
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
5. Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study.
Ding S; Cai L; Jin A; Zhou X; Yan J; Wang L; Zhao H; Wang T; Hu Y
Support Care Cancer; 2022 Apr; 30(4):3321-3327. PubMed ID: 34988704
[TBL] [Abstract][Full Text] [Related]
6. TNF-α increases the risk of bleeding in patients after CAR T-cell therapy: A bleeding model based on a real-world study of Chinese CAR T Working Party.
Qi J; Lv X; Chen J; Wang H; Chu T; Tang Y; Pan T; Zhou M; Cai C; Ren Y; Liu Y; Fan Y; Shen W; Ma X; Qiu H; Tang X; Fu C; Wu D; Han Y
Hematol Oncol; 2022 Feb; 40(1):63-71. PubMed ID: 34606093
[TBL] [Abstract][Full Text] [Related]
7. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
8. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
9. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM; Latorraca CDOC; Pacheco RL; Riera R
Eur J Haematol; 2022 Dec; 109(6):601-618. PubMed ID: 36018500
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
14. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
17. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.
Wang X; Li C; Luo W; Zhang Y; Huang Z; Xu J; Mei H; Hu Y
Ann Hematol; 2023 Dec; 102(12):3575-3585. PubMed ID: 37814134
[TBL] [Abstract][Full Text] [Related]
18. [Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].
Li YN; Du MY; Li CG; Zhang YQ; Luo WJ; Kou HM; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):739-746. PubMed ID: 34753228
[No Abstract] [Full Text] [Related]
19. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
20. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
